Grunenthal Goes Live on Argus Safety(TM) From Relsys

IRVINE, California, April 17 /PRNewswire/ --

-- German Pharmaceutical Manufacturer Deploys Argus PV(TM), Power Reports and Electronic Submissions Manager for Regulatory Compliance in Adverse Event Reporting

Relsys International, the leading provider of software solutions for adverse event reporting, pharmacovigilance and risk management for the pharmaceutical industry, announced today that its flagship product, Argus Safety Web(TM) has been deployed by The Grunenthal Group, a leading German pharmaceutical company.

Grunenthal, which employs over 4,800 people worldwide and markets products in over 100 countries, worked with Relsys' Global Professional Services group to successfully deploy the industry-leading drug safety and risk management system, and ensure effective integration into its IT infrastructure.

"When it became apparent that the drug safety system we were using wasn't going to be adequate to meet the needs of a growing company like ours, we looked for a solution that would help us meet regulatory requirements not just in Europe, but globally," noted Dr. Ralph Nies, Head of Corporate Drug Safety of Grunenthal. "Of all the commercially-available products in the market, we felt that Argus Safety from Relsys was the most comprehensive solution, and could become an integral part of our pharmacovigilance program."

"We're delighted to welcome Grunenthal into the growing number of Argus Safety users," commented Dave Bajaj, President and CEO of Relsys International. "We've designed our drug safety solutions to work on a global basis, and help our users move beyond adverse event collection and reporting and into a complete integrated environment for pharmacovigilance and risk management."

Grunenthal has deployed Argus Safety Web(TM), along with two modules -- Power Reports(TM), which provides multi-dimensional analysis of pharmaceutical safety data, and Electronic Submission Manager(TM), which provides extensive E2B report functionality.

About Relsys International

Relsys International provides a complete systems solution for pharmacovigilance and risk management that help pharmaceutical, biotech and medical device companies improve drug safety and ensure ongoing compliance with global regulations. The company, founded in 1987, works in partnership with its customers to develop and deliver innovative solutions to long-term business needs, and to provide critical components to support its clients' corporate risk management strategies. Argus Safety(TM), the company's flagship product, is the world's best selling adverse event reporting software, and is used by more of the leading pharmaceutical companies than any other solution. Relsys is a privately held company, headquartered in Irvine, California. For more information, visit www.relsys.net, or call +1-949-453-1715 (in Europe call +44-20-8849-8058).

About the Grunenthal Group

Grunenthal GmbH is an independent and international pharmaceutical company, concentrating on pain therapy, gynaecology and anti-infectives. It was founded in Stolberg in 1946. The operative unit in Germany is Grunenthal GmbH located in Aachen, where production, research and development are concentrated. The research and development pipeline contains new chemical entities and advanced pharmaceutical delivery technologies. Grunenthal GmbH is currently represented in 26 countries with affiliates in virtually all European countries. Grunenthal GmbH has production sites in seven countries. Grunenthal GmbH employs about 1,800 people in Germany and 4,800 world-wide. For more information, visit the company's website at www.grunenthal.com.

    
    Web site: http://www.relsys.net
              http://www.grunenthal.com

John Loucks of Relsys International, +1-949-453-1715, johnl@relsys.net; or Rick Sharga of CJ Patrick Company, +1-949-387-6402, rsharga@cjpatrickcompany.com, for Relsys International